title: BRCA and pancreatic cancer.
abstract: Germline mutations in BRCA genes have been associated with pancreatic cancer. Laboratory and clinical data suggest that patients with BRCA mutations may be more responsive to therapy consisting of conventional chemotherapy with a poly(ADP-ribose) polymerase inhibitor (PARPi). The most recent data from the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting will be reviewed (Abstracts #11024 and #TPS4144).
authors.affiliation: Division of GI Oncology and Experimental Therapeutics, Tufts Medical Center. Boston, MA 02111, USA.
authors.forename: Gregory T
authors.initials: GT
authors.lastname: Brennan
authors.forename: Valerie
authors.initials: V
authors.lastname: Relias
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D002986:Clinical Trials as Topic; D000076164:Fanconi Anemia Complementation Group N Protein; D018095:Germ-Line Mutation; D006801:Humans; D009687:Nuclear Proteins / Q000235:genetics*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D019313:BRCA1 Protein; D024682:BRCA2 Protein; D000076164:Fanconi Anemia Complementation Group N Protein; D009687:Nuclear Proteins; C512790:PALB2 protein, human; D025521:Tumor Suppressor Proteins